SGIOF (SGIOF) Stock Price & Analysis
SGIOF (SGIOF) rose 0.00% to USD 17.68 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
SGIOF last closed at USD 17.68; the session ranged USD 17.68–19 on volume of 500 shares. Market capitalization is $15.05B, with a 52-week range of USD 14.25–26 (PNK). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 17.68 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 17.68 |
| Open | USD 19 |
| Day Range | USD 17.68 – 19 |
| 52-Week Range | USD 14.25 – 26 |
| Volume | 500 shares |
| Market Cap | $15.05B |
| Exchange | PNK |
Technical Analysis (SGIOF)
Nexqual's technical model rates SGIOF "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 18.13 (oversold) |
| vs SMA50 | Below (USD 19.19) |
| MACD | -0.67 (negative) |
Analyst Ratings (SGIOF)
Wall Street analysts rate SGIOF "None", per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | None |
|---|
Earnings (SGIOF)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $159.33B |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (SGIOF)
| Total Revenue | $499.68B |
|---|---|
| Revenue Growth (YoY) | +32.80% |
| Gross Margin | +83.50% |
| Operating Margin | -18.60% |
| Profit Margin | +41.06% |
| ROE | +13.51% |
| Debt / Equity | 40.59 |
| Current Ratio | 1.58 |
| Total Cash | $711.40B |
| Total Debt | $684.39B |
| Free Cash Flow | $-11.20B |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (SGIOF)
Nexqual rates SGIOF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Critical — Revenue -11% YoY (annual), sharp decline |
|---|---|
| Profitability | Solid — Gross margin 83%, operating -19% |
| Balance Sheet | Solid — $711.4B cash vs $684.4B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$11.2B, burning cash |
| Efficiency | Mixed — ROE 14%, ROA 3.8% |
Ownership (SGIOF)
| Insider Ownership | +4.83% |
|---|---|
| Institutional Ownership | +60.44% |
| Shares Outstanding | 850.98M |
| Float | 850.98M |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (SGIOF)
SGIOF is led by Isao Teshirogi (age 66), CEO, President & Representative Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| CEO, President & Representative Director | Isao Teshirogi (age 66) |
|---|---|
| Vice President of Corporate Communications & Secretary Office | Yoshimasa Kyokawa |
| Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office | Yoshihiro Furuya |
| Senior Exec. Officer, SVP of R & D Supervisory Unit and Pharma. Tech. Research Div. & Director | John Apeler Keller (age 61) |
Major Backers & Investors (SGIOF)
Notable institutional backers of SGIOF include HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT., John Hancock Funds III-International Growth Fund, Fidelity, according to Nexqual as of June 10, 2026 at 02:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT. | 0.73% |
| John Hancock Funds III-International Growth Fund | 0.36% |
| Fidelity | 0.32% |
| J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF | 0.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.14% |
| BlackRock | 1.26% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGIOY | Shionogi & Co. Ltd. | USD 8.56 | ▼ 2.28% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| ALPMF | Astellas Pharma, Inc. | USD 14.26 | ▲ 0.42% |
| MKGAF | Merck KGaA | USD 159.71 | ▼ 2.48% |
| TRUMF | TERUMO CORP | USD 13.6 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.